Mitral Regurgitation

Myocor presents valve repair abstract, begins Coapsys trial

Published in Medical Letter on the CDC and FDA, December 14th, 2003

Myocor, Inc., a clinical evaluation stage medical company, announced an abstract of its TRACE feasibility trial on the Coapsys Annuloplasty System was presented at the American Heart Association scientific conference.

The abstract, "Off-Pump Mitral Valve Repair Using the Coapsys Device: Early Results in Patients with Functional Mitral Regurgitation," reports favorable outcomes on the ability of Myocor's Coapsys device to geometrically reshape the mitral valve and to improve valve function on a closed, beating heart without the use of cardiopulmonary bypass (stopping of the heart).

"Early results of the international feasibility study demonstrated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2003-12-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry